<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Cytotoxics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int500-cytotoxics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int500-cytotoxics.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int500-cytotoxics.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int995-cranberry-juice.htm" title="Previous: Cranberry Juice">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1242-brentuximab-vedotin.htm" title="Next: Brentuximab vedotin">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Cytotoxics</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Cytotoxics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>cytotoxics</span> <span>with</span> <span>clozapine</span> <span>(increased risk of agranulocytosis)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr></tbody></table><p><strong>Brentuximab vedotin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1008-bleomycin.htm">Bleomycin</a></td><td class="cAI"><p><span>increased risk of pulmonary toxicity when </span><span>brentuximab vedotin</span> <span>given with</span> <span>bleomycin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>possible increased risk of neutropenia when </span><span>brentuximab vedotin</span> <span>given with</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>effects of </span><span>brentuximab vedotin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Eribulin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>eribulin</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>eribulin</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>eribulin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>eribulin</span> <span>possibly reduced by</span> <span>St John's wort</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Vinflunine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span><span>vinflunine</span> <span>possibly increased by</span> <span>grapefruit juice</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>vinflunine</span> <span>possibly increased by</span> <span>itraconazole</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>vinflunine</span> <span>increased by</span> <span>ketoconazole</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>vinflunine</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>vinflunine</span> <span>possibly reduced by</span> <span>rifampicin</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>vinflunine</span> <span>possibly increased by</span> <span>ritonavir</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>vinflunine</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Arsenic Trioxide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>risk of ventricular arrhythmias with </span><span>arsenic trioxide</span> <span>increased by hypokalaemia caused by</span> <span>acetazolamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>amiodarone</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int242-amitriptyline.htm">Amitriptyline</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>amitriptyline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>amphotericin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>antipsychotics</span> <span>that prolong the QT interval</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int244-clomipramine.htm">Clomipramine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>clomipramine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>disopyramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>risk of ventricular arrhythmias with </span><span>arsenic trioxide</span> <span>increased by hypokalaemia caused by</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td class="cAI"><p><span>risk of ventricular arrhythmias with </span><span>arsenic trioxide</span> <span>increased by hypokalaemia caused by</span> <span>thiazides and related diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>haloperidol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int840-levofloxacin.htm">Levofloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>levofloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>lithium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>moxifloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>arsenic trioxide</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span>(possible risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>sotalol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>arsenic trioxide</span> <span>given with</span> <span>vandetanib</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Dacarbazine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td class="cAI"><p><span>avoidance of </span><span>dacarbazine</span> <span>advised by manufacturer of</span> <span>aldesleukin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Bortezomib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span><span>bortezomib</span> <span>increased by</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Trabectedin</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Protein Kinase Inhibitors</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Crizotinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>alfentanil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>atazanavir</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>beta-blockers</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly reduced by</span> <span>carbamazepine</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>clarithromycin</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>clonidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>diltiazem</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int981-ergot-alkaloids.htm">Ergot Alkaloids</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>ergot alkaloids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>fentanyl</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>grapefruit juice</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>indinavir</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>itraconazole</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>increased by</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>mefloquine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>crizotinib</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises contraceptive effect of</span> <span>oestrogens</span> <span>possibly reduced</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly reduced by</span> <span>phenobarbital</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly reduced by</span> <span>phenytoin</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int654-pilocarpine.htm">Pilocarpine</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>pilocarpine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>pimozide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises contraceptive effect of</span> <span>progestogens</span> <span>possibly reduced</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly reduced by</span> <span>rifabutin</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>reduced by</span> <span>rifampicin</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>ritonavir</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>saquinavir</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>sirolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>manufacturer of </span><span>crizotinib</span> <span>advises caution with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>telithromycin</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>possible increased risk of bradycardia when </span><span>crizotinib</span> <span>given with</span> <span>verapamil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>crizotinib</span> <span>possibly increased by</span> <span>voriconazole</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Axitinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>atazanavir</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly decreased by</span> <span>carbamazepine</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>clarithromycin</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly decreased by</span> <span>dexamethasone</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>erythromycin</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>indinavir</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>itraconazole</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>increased by</span> <span>ketoconazole</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly decreased by</span> <span>phenobarbital</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly decreased by</span> <span>phenytoin</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly decreased by</span> <span>rifabutin</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>decreased by</span> <span>rifampicin</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>saquinavir</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>axitinib</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—consider increasing dose of <span>axitinib</span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>plasma  concentration of </span><span>axitinib</span> <span>possibly increased by</span> <span>telithromycin</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr></tbody></table><p><strong>Ruxolitinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>boceprevir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>clarithromycin</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>fluconazole</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>indinavir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>itraconazole</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>ketoconazole</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>lopinavir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>posaconazole</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>ruxolitinib</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>ritonavir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>saquinavir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>telaprevir</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>telithromycin</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ruxolitinib</span> <span>given with</span> <span>voriconazole</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr></tbody></table><p><strong>Vemurafenib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises contraceptive effect of</span> <span>oestrogens</span> <span>possibly reduced</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises contraceptive effect of</span> <span>progestogens</span> <span>possibly reduced</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span><span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>vemurafenib</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Vandetanib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>amisulpride</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>arsenic trioxide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>artemether with lumefantrine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span><span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>chlorpromazine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>disopyramide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with <em>parenteral</em></span> <span>erythromycin</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>haloperidol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>methadone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>mizolastine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>moxifloxacin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>ondansetron</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>pentamidine isetionate</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span><span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>manufacturer of </span><span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>proton pump inhibitors</span> <span>(absorption of <span>vandetanib</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span><span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span>(plasma concentration of <span>vandetanib</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>sotalol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span><span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>sulpiride</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int582-toremifene.htm">Toremifene</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>toremifene</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>vandetanib</span> <span>given with</span> <span>zuclopenthixol</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Pazopanib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>pazopanib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span><span>pazopanib</span> <span>possibly reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span><span>—manufacturer of <span>pazopanib</span> advises give at least 2 hours before or 10 hours after <span>histamine H<sub>2</sub>-antagonists</span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td><p><span>plasma concentration of </span><span>pazopanib</span> <span>increased by</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span><span>pazopanib</span> <span>possibly reduced by</span> <span>proton pump inhibitors</span><span>—manufacturer of <span>pazopanib</span> advises give at the same time as <span>proton pump inhibitors</span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Gefitinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>gefitinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span><span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of </span><span>gefitinib</span> <span>increased by</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span><span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span><span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int747-ranitidine.htm">Ranitidine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>gefitinib</span> <span>reduced by</span> <span>ranitidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>gefitinib</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span><span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>gefitinib</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Everolimus</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>atazanavir</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>increased by</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>clarithromycin</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>darunavir</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>increased by</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>manufacturer of </span><span>everolimus</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>indinavir</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>itraconazole</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>increased by</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>posaconazole</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>ritonavir</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>saquinavir</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>telithromycin</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span><span>everolimus</span> <span>given with</span> <span>verapamil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>everolimus</span> <span>possibly increased by</span> <span>voriconazole</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Temsirolimus</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> The main active metabolite of temsirolimus is sirolimus—<em>see also</em> interactions of sirolimus and consult product literature</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of active metabolite of </span><span>temsirolimus</span> <span>increased by</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of active metabolite of </span><span>temsirolimus</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Lapatinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>lapatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lapatinib</span> <span>reduced by</span> <span>carbamazepine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span>possible increased risk of neutropenia when </span><span>lapatinib</span> <span>given with</span> <span>docetaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span><span>lapatinib</span> <span>possibly reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td class="cAI"><p><span></span> <span>lapatinib</span> <span>increases plasma concentration of active metabolite of</span> <span>irinotecan</span><span>—consider reducing dose of <span>irinotecan</span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lapatinib</span> <span>increased by</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int517-paclitaxel.htm">Paclitaxel</a></td><td class="cAI"><p><span>increased risk of neutropenia when </span><span>lapatinib</span> <span>given with</span> <span>paclitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td><p><span></span> <span>lapatinib</span> <span>increases plasma concentration of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>pimozide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>posaconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span><span>lapatinib</span> <span>possibly reduced by</span> <span>proton pump inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>repaglinide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Nilotinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>nilotinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span><span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>nilotinib</span> <span>increased by</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>nilotinib</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>nilotinib</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>nilotinib</span> <span>possibly increased by</span> <span>ritonavir</span><span>—manufacturer of <span>nilotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sunitinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>sunitinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span><span>sunitinib</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>sunitinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Sorafenib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>sorafenib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>sorafenib</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span></span> <span>sorafenib</span> <span>increases plasma concentration of</span> <span>docetaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td><p><span></span> <span>sorafenib</span> <span>possibly increases plasma concentration of</span> <span>doxorubicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td><p><span></span> <span>sorafenib</span> <span>possibly increases plasma concentration of</span> <span>irinotecan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>bioavailability of </span><span>sorafenib</span> <span>reduced by</span> <span>neomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>sorafenib</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Imatinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>imatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>imatinib</span> <span>reduced by</span> <span>carbamazepine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>imatinib</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span><span>imatinib</span> <span>increased by</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int738-levothyroxine.htm">Levothyroxine</a></td><td><p><span></span> <span>imatinib</span> <span>possibly reduces plasma concentration of</span> <span>levothyroxine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>imatinib</span> <span>reduced by</span> <span>oxcarbazepine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span>manufacturer of </span><span>imatinib</span> <span>advises caution with</span> <span>paracetamol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>imatinib</span> <span>reduced by</span> <span>phenytoin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>imatinib</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>imatinib</span> <span>increases plasma concentration of</span> <span>simvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>imatinib</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>imatinib</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span>manufacturer of </span><span>imatinib</span> <span>advises replacement of</span> <span>warfarin</span> <span>with a heparin (possibility of enhanced <span>warfarin</span> effect)</span></p></td><td></td></tr></tbody></table><p><strong>Erlotinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td class="cAI"><p><span>plasma concentration of </span><span>erlotinib</span> <span>possibly reduced by</span> <span>antacids</span><span>—give <span>antacids</span> at least 4 hours before or 2 hours after <span>erlotinib</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>erlotinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int923-capecitabine.htm">Capecitabine</a></td><td><p><span>plasma concentration of </span><span>erlotinib</span> <span>possibly increased by</span> <span>capecitabine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Capecitabine is a prodrug of fluorouracil</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span><span>erlotinib</span> <span>increased by</span> <span>ciprofloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>erlotinib</span> <span>given with</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>esomeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int745-famotidine.htm">Famotidine</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>famotidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span><span>erlotinib</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>lansoprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>erlotinib</span> <span>given with</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int746-nizatidine.htm">Nizatidine</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>nizatidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>erlotinib</span> <span>reduced by</span> <span>omeprazole</span><span>—manufacturer of <span>erlotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int754-pantoprazole.htm">Pantoprazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>pantoprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int869-rabeprazole.htm">Rabeprazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>rabeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int747-ranitidine.htm">Ranitidine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>erlotinib</span> <span>reduced by</span> <span>ranitidine</span><span>—manufacturer of <span>erlotinib</span> advises give at least 2 hours before or 10 hours after <span>ranitidine</span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>erlotinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Dasatinib</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>dasatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int745-famotidine.htm">Famotidine</a></td><td><p><span>plasma concentration of </span><span>dasatinib</span> <span>possibly reduced by</span> <span>famotidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span><span>dasatinib</span> <span>possibly increased by</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span><span>dasatinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>dasatinib</span> <span>possibly increases plasma concentration of</span> <span>simvastatin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Vinorelbine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>possible increased risk of neutropenia when </span><span>vinorelbine</span> <span>given with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>metabolism of </span><span>vinorelbine</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span>(increased risk of neurotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>vinorelbine</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr></tbody></table><p><strong>Mitotane</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>mitotane</span> <span>possibly reduces anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int549-spironolactone.htm">Spironolactone</a></td><td><p><span>manufacturer of </span><span>mitotane</span> <span>advises avoid concomitant use of</span> <span>spironolactone</span> <span>(antagonism of effect)</span></p></td><td></td></tr></tbody></table><p><strong>Hydroxycarbamide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>hydroxycarbamide</span> <span>given with</span> <span>didanosine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int401-stavudine.htm">Stavudine</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>hydroxycarbamide</span> <span>given with</span> <span>stavudine</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Bexarotene</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>plasma concentration of </span><span>bexarotene</span> <span>increased by</span> <span>gemfibrozil</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Etoposide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>plasma concentration of </span><span>etoposide</span> <span>possibly increased by</span> <span>atovaquone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>plasma concentration of </span><span>etoposide</span> <span>possibly increased by</span> <span>ciclosporin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>etoposide</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>etoposide</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>etoposide</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Irinotecan</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>metabolism of </span><span>irinotecan</span> <span>possibly inhibited by</span> <span>atazanavir</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>irinotecan</span> <span>and its active metabolite reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>irinotecan</span> <span>reduced by</span> <span>ketoconazole</span> <span>(but concentration of active metabolite of irinotecan increased)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>plasma concentration of active metabolite of </span><span>irinotecan</span> <span>increased by</span> <span>lapatinib</span><span>—consider reducing dose of <span>irinotecan</span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>irinotecan</span> <span>and its active metabolite reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>irinotecan</span> <span>and its active metabolite reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span>plasma concentration of </span><span>irinotecan</span> <span>possibly increased by</span> <span>sorafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>metabolism of </span><span>irinotecan</span> <span>accelerated by</span> <span>St John's wort</span> <span>(reduced plasma concentration—avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Vinblastine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td class="cAI"><p><span>avoidance of </span><span>vinblastine</span> <span>advised by manufacturer of</span> <span>aldesleukin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>toxicity of </span><span>vinblastine</span> <span>increased by</span> <span>erythromycin</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>vinblastine</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>metabolism of </span><span>vinblastine</span> <span>possibly inhibited by</span> <span>posaconazole</span> <span>(increased risk of neurotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>vinblastine</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Alkylating Drugs</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Bendamustine</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Estramustine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int461-sodium-clodronate.htm">Sodium Clodronate</a></td><td class="cAI"><p><span>plasma concentration of </span><span>estramustine</span> <span>increased by</span> <span>sodium clodronate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Carmustine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>myelosuppressive effects of  </span><span>carmustine</span> <span>possibly enhanced by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>carmustine</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr></tbody></table><p><strong>Lomustine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>myelosuppressive effects of  </span><span>lomustine</span> <span>possibly enhanced by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Busulfan</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>metabolism of </span><span>busulfan</span> <span>inhibited by</span> <span>itraconazole</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int170-metronidazole.htm">Metronidazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>busulfan</span> <span>increased by</span> <span>metronidazole</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical metronidazole preparations </p></div></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span>metabolism of <em>intravenous</em></span> <span>busulfan</span> <span>possibly inhibited by</span> <span>paracetamol</span> <span>(manufacturer of <em>intravenous</em><span>busulfan</span> advises caution within 72 hours of <span>paracetamol</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>busulfan</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1041-tioguanine.htm">Tioguanine</a></td><td><p><span>increased risk of hepatotoxicity when </span><span>busulfan</span> <span>given with</span> <span>tioguanine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cyclophosphamide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>cyclophosphamide</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>side-effects of </span><span>cyclophosphamide</span> <span>possibly increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>side-effects of </span><span>cyclophosphamide</span> <span>possibly increased by</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int513-pentostatin.htm">Pentostatin</a></td><td class="cAI"><p><span>increased toxicity when high-dose </span><span>cyclophosphamide</span> <span>given with</span> <span>pentostatin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>cyclophosphamide</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Ifosfamide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int877-cisplatin.htm">Cisplatin</a></td><td><p><span>increased risk of otoxicity when </span><span>ifosfamide</span> <span>given with</span> <span>cisplatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>ifosfamide</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr></tbody></table><p><strong>Melphalan</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>melphalan</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>melphalan</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int196-nalidixic-acid.htm">Nalidixic Acid</a></td><td><p><span>increased risk of </span><span>melphalan</span> <span>toxicity when given with</span> <span>nalidixic acid</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Thiotepa</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>thiotepa</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Antibiotics (cytotoxic)</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Mitoxantrone</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>excretion of </span><span>mitoxantrone</span> <span>reduced by</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Idarubicin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>idarubicin</span> <span>increased by</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Mitomycin</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Epirubicin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>epirubicin</span> <span>increased by</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>epirubicin</span> <span>increased by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Bleomycin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1242-brentuximab-vedotin.htm">Brentuximab vedotin</a></td><td class="cAI"><p><span>increased risk of pulmonary toxicity when </span><span>bleomycin</span> <span>given with</span> <span>brentuximab vedotin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int877-cisplatin.htm">Cisplatin</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>bleomycin</span> <span>given with</span> <span>cisplatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>bleomycin</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr></tbody></table><p><strong>Doxorubicin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of neurotoxicity when </span><span>doxorubicin</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>doxorubicin</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span>plasma concentration of </span><span>doxorubicin</span> <span>possibly increased by</span> <span>sorafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int401-stavudine.htm">Stavudine</a></td><td><p><span></span> <span>doxorubicin</span> <span>possibly inhibits effects of</span> <span>stavudine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>plasma concentration of </span><span>doxorubicin</span> <span>possibly increased by</span> <span>verapamil</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Antimetabolites</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Decitabine</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Pemetrexed</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td class="cAI"><p><span>antifolate effect of </span><span>pemetrexed</span> <span>increased by</span> <span>pyrimethamine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Raltitrexed</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int860-folates.htm">Folates</a></td><td class="cAI"><p><span>manufacturer of </span><span>raltitrexed</span> <span>advises avoid concomitant use with</span> <span>folates</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Gemcitabine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>gemcitabine</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tioguanine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td><p><span>increased risk of hepatotoxicity when </span><span>tioguanine</span> <span>given with</span> <span>busulfan</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cytarabine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>cytarabine</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int820-flucytosine.htm">Flucytosine</a></td><td><p><span></span> <span>cytarabine</span> <span>possibly reduces plasma concentration of</span> <span>flucytosine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int508-fludarabine.htm">Fludarabine</a></td><td><p><span>intracellular concentration of </span><span>cytarabine</span> <span>increased by</span> <span>fludarabine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fludarabine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int821-cytarabine.htm">Cytarabine</a></td><td><p><span></span> <span>fludarabine</span> <span>increases intracellular concentration of</span> <span>cytarabine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int362-dipyridamole.htm">Dipyridamole</a></td><td><p><span>effects of </span><span>fludarabine</span> <span>possibly reduced by</span> <span>dipyridamole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int513-pentostatin.htm">Pentostatin</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>fludarabine</span> <span>given with</span> <span>pentostatin</span> <span>(unacceptably high incidence of fatalities)</span></p></td><td></td></tr></tbody></table><p><strong>Fluorouracil</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span><span>fluorouracil</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>fluorouracil</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int565-filgrastim.htm">Filgrastim</a></td><td><p><span>neutropenia possibly exacerbated when </span><span>fluorouracil</span> <span>given with</span> <span>filgrastim</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int170-metronidazole.htm">Metronidazole</a></td><td><p><span>metabolism of </span><span>fluorouracil</span> <span>inhibited by</span> <span>metronidazole</span> <span>(increased toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical metronidazole preparations </p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>fluorouracil</span> <span>possibly inhibits metabolism of</span> <span>phenytoin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int957-temoporfin.htm">Temoporfin</a></td><td class="cAI"><p><span>increased skin photosensitivity when <em>topical</em></span> <span>fluorouracil</span> <span>used with</span> <span>temoporfin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Capecitabine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Capecitabine is a prodrug of fluorouracil</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td class="cAI"><p><span>manufacturer of </span><span>capecitabine</span> <span>advises avoid concomitant use with</span> <span>allopurinol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td><p><span></span> <span>capecitabine</span> <span>possibly increases plasma concentration of</span> <span>erlotinib</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tegafur with uracil</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Tegafur is a prodrug of fluorouracil</p></div><p><strong>Mercaptopurine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td class="cAI"><p><span>enhanced effects and increased toxicity of </span><span>mercaptopurine</span> <span>when given with</span> <span>allopurinol</span> <span>(reduce dose of <span>mercaptopurine</span> to one quarter of usual dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int928-aminosalicylates.htm">Aminosalicylates</a></td><td><p><span>possible increased risk of leucopenia when </span><span>mercaptopurine</span> <span>given with</span> <span>aminosalicylates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>mercaptopurine</span> <span>possibly reduces anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1178-febuxostat.htm">Febuxostat</a></td><td class="cAI"><p><span>avoidance of </span><span>mercaptopurine</span> <span>advised by manufacturer of</span> <span>febuxostat</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int208-sulfamethoxazole.htm">Sulfamethoxazole</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>mercaptopurine</span> <span>given with</span> <span>sulfamethoxazole</span> <span>(as co-trimoxazole)</span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>mercaptopurine</span> <span>given with</span> <span>trimethoprim</span> <span>(also with co-trimoxazole)</span></p></td><td></td></tr></tbody></table><p><strong>Methotrexate</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td><p><span>excretion of </span><span>methotrexate</span> <span>increased by alkaline urine due to</span> <span>acetazolamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int683-acitretin.htm">Acitretin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>methotrexate</span> <span>increased by</span> <span>acitretin</span> <span>(also increased risk of hepatotoxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>aspirin</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>risk of toxicity when </span><span>methotrexate</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>excretion of </span><span>methotrexate</span> <span>possibly reduced by</span> <span>ciprofloxacin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int877-cisplatin.htm">Cisplatin</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>methotrexate</span> <span>given with</span> <span>cisplatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int64-diclofenac.htm">Diclofenac</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>diclofenac</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>methotrexate</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span>increased risk of </span><span>methotrexate</span> <span>toxicity when given with</span> <span>doxycycline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int783-ibuprofen.htm">Ibuprofen</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>ibuprofen</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int70-indometacin.htm">Indometacin</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>indometacin</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int71-ketoprofen.htm">Ketoprofen</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>ketoprofen</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td class="cAI"><p><span>risk of toxicity when </span><span>methotrexate</span> <span>given with</span> <span>leflunomide</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int74-meloxicam.htm">Meloxicam</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>meloxicam</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>probably reduced by</span> <span>NSAIDs</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int76-naproxen.htm">Naproxen</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>naproxen</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>absorption of </span><span>methotrexate</span> <span>possibly reduced by</span> <span>neomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int52-nitrous-oxide.htm">Nitrous Oxide</a></td><td class="cAI"><p><span>antifolate effect of </span><span>methotrexate</span> <span>increased by</span> <span>nitrous oxide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int174-penicillins.htm">Penicillins</a></td><td><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>penicillins</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>antifolate effect of </span><span>methotrexate</span> <span>increased by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>methotrexate</span> <span>reduced by</span> <span>probenecid</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>excretion of </span><span>methotrexate</span> <span>possibly reduced by</span> <span>proton pump inhibitors</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td class="cAI"><p><span>antifolate effect of </span><span>methotrexate</span> <span>increased by</span> <span>pyrimethamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int208-sulfamethoxazole.htm">Sulfamethoxazole</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>methotrexate</span> <span>given with</span> <span>sulfamethoxazole</span> <span>(as co-trimoxazole)</span></p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td><p><span>increased risk of </span><span>methotrexate</span> <span>toxicity when given with</span> <span>sulfonamides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int216-tetracycline.htm">Tetracycline</a></td><td><p><span>increased risk of </span><span>methotrexate</span> <span>toxicity when given with</span> <span>tetracycline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>methotrexate</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>methotrexate</span> <span>given with</span> <span>trimethoprim</span> <span>(also with co-trimoxazole)</span></p></td><td></td></tr></tbody></table><p><strong>Pentostatin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int502-cyclophosphamide.htm">Cyclophosphamide</a></td><td class="cAI"><p><span>increased toxicity when </span><span>pentostatin</span> <span>given with high-dose</span> <span>cyclophosphamide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int508-fludarabine.htm">Fludarabine</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>pentostatin</span> <span>given with</span> <span>fludarabine</span> <span>(unacceptably high incidence of fatalities)</span></p></td><td></td></tr></tbody></table><p><strong>Platinum Compounds</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>platinum compounds</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int137-capreomycin.htm">Capreomycin</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>platinum compounds</span> <span>given with</span> <span>capreomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>platinum compounds</span> <span>given with</span> <span>diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>platinum compounds</span> <span>given with</span> <span>polymyxins</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Carboplatin</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Cisplatin</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td class="cAI"><p><span>avoidance of </span><span>cisplatin</span> <span>advised by manufacturer of</span> <span>aldesleukin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1008-bleomycin.htm">Bleomycin</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>cisplatin</span> <span>given with</span> <span>bleomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int825-ifosfamide.htm">Ifosfamide</a></td><td><p><span>increased risk of otoxicity when </span><span>cisplatin</span> <span>given with</span> <span>ifosfamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span>increased pulmonary toxicity when </span><span>cisplatin</span> <span>given with</span> <span>methotrexate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>cisplatin</span> <span>possibly reduces plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>cisplatin</span> <span>given with</span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Oxaliplatin</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Procarbazine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>disulfiram-like reaction when </span><span>procarbazine</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>procarbazine</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr></tbody></table><p><strong>Temozolomide</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span><span>temozolomide</span> <span>increased by</span> <span>valproate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Vincristine</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>vincristine</span> <span>possibly reduces absorption of</span> <span>digoxin</span> <span><em>tablets</em></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>metabolism of </span><span>vincristine</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span>(increased risk of neurotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span>metabolism of </span><span>vincristine</span> <span>possibly inhibited by</span> <span>nifedipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>vincristine</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>metabolism of </span><span>vincristine</span> <span>possibly inhibited by</span> <span>posaconazole</span> <span>(increased risk of neurotoxicity)</span></p></td><td></td></tr></tbody></table><p><strong>Taxanes</strong> belongs to <strong>Cytotoxics</strong> but has no specific interaction information.</p><p><strong>Cabazitaxel</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>cabazitaxel</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Docetaxel</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span><em>in vitro</em> studies suggest a possible interaction between </span><span>docetaxel</span> <span>and</span> <span>ciclosporin</span> <span>(consult <span>docetaxel</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span><em>in vitro</em> studies suggest a possible interaction between </span><span>docetaxel</span> <span>and</span> <span>erythromycin</span> <span>(consult <span>docetaxel</span> product literature)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span><em>in vitro</em> studies suggest a possible interaction between </span><span>docetaxel</span> <span>and</span> <span>ketoconazole</span> <span>(consult <span>docetaxel</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td><p><span>possible increased risk of neutropenia when </span><span>docetaxel</span> <span>given with</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>docetaxel</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span>plasma concentration of </span><span>docetaxel</span> <span>increased by</span> <span>sorafenib</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Paclitaxel</strong> belongs to <strong>Cytotoxics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>increased risk of neutropenia when </span><span>paclitaxel</span> <span>given with</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>paclitaxel</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1242-brentuximab-vedotin.htm" title="Brentuximab vedotin">Brentuximab vedotin</a></li><li><a href="bnf_int1205-eribulin.htm" title="Eribulin">Eribulin</a></li><li><a href="bnf_int1181-vinflunine.htm" title="Vinflunine">Vinflunine</a></li><li><a href="bnf_int1168-arsenic-trioxide.htm" title="Arsenic Trioxide">Arsenic Trioxide</a></li><li><a href="bnf_int1167-dacarbazine.htm" title="Dacarbazine">Dacarbazine</a></li><li><a href="bnf_int1116-bortezomib.htm" title="Bortezomib">Bortezomib</a></li><li><a href="bnf_int1103-trabectedin.htm" title="Trabectedin">Trabectedin</a></li><li id="_bnf_int1087-protein-kinase-inhibitors"><a href="bnf_int1087-protein-kinase-inhibitors.htm" title="Protein Kinase Inhibitors">Protein Kinase Inhibitors</a></li><li><a href="bnf_int1085-vinorelbine.htm" title="Vinorelbine">Vinorelbine</a></li><li><a href="bnf_int1057-mitotane.htm" title="Mitotane">Mitotane</a></li><li><a href="bnf_int1052-hydroxycarbamide.htm" title="Hydroxycarbamide">Hydroxycarbamide</a></li><li><a href="bnf_int1046-bexarotene.htm" title="Bexarotene">Bexarotene</a></li><li><a href="bnf_int1031-etoposide.htm" title="Etoposide">Etoposide</a></li><li><a href="bnf_int1006-irinotecan.htm" title="Irinotecan">Irinotecan</a></li><li><a href="bnf_int1002-vinblastine.htm" title="Vinblastine">Vinblastine</a></li><li id="_bnf_int501-alkylating-drugs"><a href="bnf_int501-alkylating-drugs.htm" title="Alkylating Drugs">Alkylating Drugs</a></li><li id="_bnf_int505-antibiotics-cytotoxic"><a href="bnf_int505-antibiotics-cytotoxic.htm" title="Antibiotics (cytotoxic)">Antibiotics (cytotoxic)</a></li><li id="_bnf_int507-antimetabolites"><a href="bnf_int507-antimetabolites.htm" title="Antimetabolites">Antimetabolites</a></li><li><a href="bnf_int513-pentostatin.htm" title="Pentostatin">Pentostatin</a></li><li id="_bnf_int512-platinum-compounds"><a href="bnf_int512-platinum-compounds.htm" title="Platinum Compounds">Platinum Compounds</a></li><li><a href="bnf_int514-procarbazine.htm" title="Procarbazine">Procarbazine</a></li><li><a href="bnf_int885-temozolomide.htm" title="Temozolomide">Temozolomide</a></li><li><a href="bnf_int815-vincristine.htm" title="Vincristine">Vincristine</a></li><li id="_bnf_int515-taxanes"><a href="bnf_int515-taxanes.htm" title="Taxanes">Taxanes</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int995-cranberry-juice.htm">Previous: Cranberry Juice</a> | <a class="top" href="bnf_int500-cytotoxics.htm#">Top</a> | <a accesskey="]" href="bnf_int1242-brentuximab-vedotin.htm">Next: Brentuximab vedotin</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>